«This was the first robust assessment to determine the impact of
baseline tumor size on clinical endpoints in patients with metastatic melanoma — in particular — those receiving MK - 3475.
Not exact matches
The three study groups had a similar distribution of
baseline characteristics, with the exception of
tumor size.